- Drugs
- Tuesday, 17 Sep 2019
Aphria Inc.'s Jamaican Subsidiary, Marigold, Receives Retail Herb House Licence
Aphria Inc. announced that its subsidiary Marigold Projects Jamaica Limited ("Marigold") has received a retail Herb House license from Jamaica's Cannabis Licensing Authority ("CLA") to open its first store in Kingston, Jamaica.
Aphria, Inc. is engaged in the production and supply of medical cannabis. It operates through three reportable segments including cannabis operations, distribution operations, and business under development. The Cannabis Operations segment produces, distributes, and sells both medical and adult-use cannabis. The Distribution Operations segment are carried out through its wholly owned subsidiaries ABP, FL Group, and CC Pharma. The Distribution under Development segment includes operations in which the firm has not received final licensing or has not commenced commercial sales from operations. The company offers medical cannabis of various strains, including Kusawa, Tamaracouta, Panache, Churchill and Iroquois. The Company is also engaged in the research and development, and commercial production of cannabis oil. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada. Aphria’s subsidiaries include Pure Natures Wellness Inc. that are engaged in the production and distribution of medical marijuana, and Cannway Pharmaceuticals Ltd., which specializes in offering support services to veterans and their first responders.
Related Industry Updates
Asia Pacific Transdermal Drug Delivery System Market Prospects & Upcoming Trends and Opportunities Upto 2027
Sep 05, 2020
Purina Pro Plan Announces the First and Only Allergen-Reducing Cat Food
Feb 26, 2020
Investors Hunting for Winners in Ashes of Industry Fire up Rally in Cannabis Stocks
Jan 24, 2020
Asia and Africa Lateral Flow Assay Market is expected to reach US$ 2,159.62 million by 2028
May 23, 2023
Biotin Supplements Market Pegged for Robust Expansion by 2027
Dec 12, 2020
Moderna picks drugmaker Catalent to manufacture potential COVID-19 vaccine
Jun 25, 2020
Sickle Cell Disease Treatment Market is expected to reach US$ 4,691.87 million by 2030
Nov 07, 2023